Active immunisation for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 50 through 59 years of age who are at increased risk for RSV disease

Brand : Arexvy

RSV Green Book Chapter updated February 2025

Passive protection against lower respiratory tract disease caused by respiratory syncytial virus in infants from birth through 6 months of age following maternal immunisation during pregnancy and active immunisation of individuals aged ≥60 years for the prevention of lower respiratory tract disease caused by respiratory syncytial virus

Rationale 6

Respiratory syncytial virus

Passive immunisation against respiratory syncytial virus (RSV) in at risk pre-term infants

Rationale:1,2

Policy from the Department of Health and Social care extends eligibility for palivizumab in the treatment of passive immunisation against respiratory syncytial virus (RSV) in at risk pre-term infants